[EN] INDOLINONE COMPOUNDS FOR THE TREATMENT OF DISEASE<br/>[FR] COMPOSES D'INDOLINONE POUR LE TRAITEMENT DE MALADIES
申请人:SUGEN, INC.
公开号:WO1996040116A1
公开(公告)日:1996-12-19
(EN) The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.(FR) Molécules organiques aptes à moduler la transduction de signaux de la tyrosine-kinase afin de réguler, de moduler et/ou d'inhiber une prolifération cellulaire anormale.
本发明涉及有机分子,能够调节酪氨酸激酶信号传导,以调节、调制和/或抑制异常细胞增殖。
3-(4'-bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
申请人:——
公开号:US20010027207A1
公开(公告)日:2001-10-04
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
本发明涉及有机分子,能够调节酪氨酸激酶信号转导,以调节、调控和/或抑制异常细胞增殖。
3-(4'-Bromobenzylindenyl)-2-indolinone and analogues thereof for the treatment of disease
申请人:SUGEN, INC.
公开号:US20030176487A1
公开(公告)日:2003-09-18
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
本发明涉及有机分子,能够调节酪氨酸激酶信号传导,以调节、调控和/或抑制异常细胞增殖。
Indolinone combinatorial libraries and related products and methods for the treatment of disease
申请人:——
公开号:US20020102608A1
公开(公告)日:2002-08-01
The present invention relates to organic molecules capable of modulating tyrosine kinase signal transduction in order to regulate, modulate and/or inhibit abnormal cell proliferation.
本发明涉及能够调节酪氨酸激酶信号转导以调节、调制和/或抑制异常细胞增殖的有机分子。
Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
申请人:Pharmacia Corporation
公开号:US20030119895A1
公开(公告)日:2003-06-26
The present invention provides methods and compositions useful for treatment or prevention of neoplasia by administering a combination comprising a 3-heteroaryl-2-indolinone compound and a COX-2 selective inhibitor. Further provided are compositions, pharmaceutical compositions, and kits for treatment and prevention of neoplasia.